CTLA4 and cancer: Novel cancer immunotherapies such as anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and anti-programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) monoclonal antibodies have revolutionised cancer therapy [1,2].